We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Newly-Developed Enzyme Could Treat Mysterious Multisystem Complications of COVID-19

By HospiMedica International staff writers
Posted on 11 Aug 2020
Print article
Illustration
Illustration
Scientists have developed a first-in-class DNASE1L3 enzyme analog, NTR-441, that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19.

The enzyme has been developed by Neutrolis (Cambridge, MA, USA), a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body. NTR-441, an engineered analog of the natural NET-destroying enzyme DNASE1L3, is the world's first investigational drug that can be systemically delivered to accurately target NETs.

NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. NETs are sticky, web-like structures made of chromatin—DNA studded with structural proteins—and expelled by suicidal neutrophils. NETs block air sacs and blood vessels in the lungs, trigger hyperinflammation and blood clotting (thrombosis), potentially causing irreversible end-organ damage and death.

Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19. In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs. NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.

"We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. "Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body. Thanks in part to competitive funding from the National Institutes of Health (R43HL150944), we will test whether NTR-441 is effective in ARDS, the most lethal manifestation of COVID-19."

Related Links:

Neutrolis

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
12-Channel PC-Based EKG
Avante Velocity EKG

Print article

Channels

Critical Care

view channel
Image: A full readout from the new AI algorithm that helps read EEGs (Photo courtesy of Duke University)

AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients

Electroencephalography (EEG) readings are crucial for detecting when unconscious patients may be experiencing or are at risk of seizures. EEGs involve placing small sensors on the scalp to measure the... Read more

Surgical Techniques

view channel
Image: GI procedures can produce dangerous levels of smoke (Photo courtesy of 123RF)

Study Warns Against Dangerous Smoke Levels Produced During Endoscopic Gastrointestinal Procedures

Healthcare professionals involved in certain smoke-generating endoscopic gastrointestinal procedures, such as those using electrical current to excise polyps, may be exposed to toxin levels comparable... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more